These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 24579927)

  • 1. Phosphatase of regenerating liver: a novel target for cancer therapy.
    Campbell AM; Zhang ZY
    Expert Opin Ther Targets; 2014 May; 18(5):555-69. PubMed ID: 24579927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting PRL phosphatases in hematological malignancies.
    Xiao S; Chen H; Bai Y; Zhang ZY; Liu Y
    Expert Opin Ther Targets; 2024 Apr; 28(4):259-271. PubMed ID: 38653737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PRL phosphatases as potential molecular targets in cancer.
    Stephens BJ; Han H; Gokhale V; Von Hoff DD
    Mol Cancer Ther; 2005 Nov; 4(11):1653-61. PubMed ID: 16275986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphatases of regenerating liver: a novel target in human solid tumors.
    Zhao WB; Wang X
    Chin Med J (Engl); 2008 Aug; 121(15):1469-74. PubMed ID: 18959128
    [No Abstract]   [Full Text] [Related]  

  • 5. PRL-1 tyrosine phosphatase regulates c-Src levels, adherence, and invasion in human lung cancer cells.
    Achiwa H; Lazo JS
    Cancer Res; 2007 Jan; 67(2):643-50. PubMed ID: 17234774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms of the PRL phosphatases.
    Rios P; Li X; Köhn M
    FEBS J; 2013 Jan; 280(2):505-24. PubMed ID: 22413991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRL-3 phosphatase and cancer metastasis.
    Al-Aidaroos AQ; Zeng Q
    J Cell Biochem; 2010 Dec; 111(5):1087-98. PubMed ID: 21053359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting phosphatases of regenerating liver (PRLs) in cancer.
    Wei M; Korotkov KV; Blackburn JS
    Pharmacol Ther; 2018 Oct; 190():128-138. PubMed ID: 29859177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice.
    Guo K; Tang JP; Tan CP; Wang H; Zeng Q
    Cancer Biol Ther; 2008 May; 7(5):750-7. PubMed ID: 18364570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage.
    Daouti S; Li WH; Qian H; Huang KS; Holmgren J; Levin W; Reik L; McGady DL; Gillespie P; Perrotta A; Bian H; Reidhaar-Olson JF; Bliss SA; Olivier AR; Sergi JA; Fry D; Danho W; Ritland S; Fotouhi N; Heimbrook D; Niu H
    Cancer Res; 2008 Feb; 68(4):1162-9. PubMed ID: 18281492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphatase of regenerating liver-1 promotes cell migration and invasion and regulates filamentous actin dynamics.
    Nakashima M; Lazo JS
    J Pharmacol Exp Ther; 2010 Aug; 334(2):627-33. PubMed ID: 20484558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and Evaluation of PRL Trimer Disruptors for Novel Anticancer Agents.
    Bai Y; Yu ZH; Zhang ZY
    Methods Mol Biol; 2016; 1447():121-38. PubMed ID: 27514804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Procyanidins Negatively Affect the Activity of the Phosphatases of Regenerating Liver.
    Stadlbauer S; Rios P; Ohmori K; Suzuki K; Köhn M
    PLoS One; 2015; 10(7):e0134336. PubMed ID: 26226290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The metastasis-promoting phosphatase PRL-3 shows activity toward phosphoinositides.
    McParland V; Varsano G; Li X; Thornton J; Baby J; Aravind A; Meyer C; Pavic K; Rios P; Köhn M
    Biochemistry; 2011 Sep; 50(35):7579-90. PubMed ID: 21806020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Pharmacological Inhibition of the Catalytic Activity of Phosphatases of Regenerating Liver in Early T Cell Receptor Signaling Dynamics and IL-2 Production.
    Aguilar-Sopeña O; Hernández-Pérez S; Alegre-Gómez S; Castro-Sánchez P; Iglesias-Ceacero A; Lazo JS; Roda-Navarro P
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Targeting of Oncogenic Tyrosine Phosphatases.
    Frankson R; Yu ZH; Bai Y; Li Q; Zhang RY; Zhang ZY
    Cancer Res; 2017 Nov; 77(21):5701-5705. PubMed ID: 28855209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiological and oncogenic roles of the PRL phosphatases.
    Hardy S; Kostantin E; Hatzihristidis T; Zolotarov Y; Uetani N; Tremblay ML
    FEBS J; 2018 Nov; 285(21):3886-3908. PubMed ID: 29770564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRL-3 promotes the motility, invasion, and metastasis of LoVo colon cancer cells through PRL-3-integrin beta1-ERK1/2 and-MMP2 signaling.
    Peng L; Xing X; Li W; Qu L; Meng L; Lian S; Jiang B; Wu J; Shou C
    Mol Cancer; 2009 Nov; 8():110. PubMed ID: 19930715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphatase of regenerating liver maintains cellular magnesium homeostasis.
    Yoshida A; Funato Y; Miki H
    Biochem J; 2018 Mar; 475(6):1129-1139. PubMed ID: 29487165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphatase PRL-3 is a direct regulatory target of TGFbeta in colon cancer metastasis.
    Jiang Y; Liu XQ; Rajput A; Geng L; Ongchin M; Zeng Q; Taylor GS; Wang J
    Cancer Res; 2011 Jan; 71(1):234-44. PubMed ID: 21084277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.